Neurocrine Announces Successful Completion of Phase Ib T-Force Study of VMAT2 Inhibitor NBI-98854 in Adolescents and Children with Tourette Syndrome
December 16, 2015 at 16:06 PM EST
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has successfully completed the Phase Ib T-Force study of NBI-98854 ...